<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709991</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT04709991</nct_id>
  </id_info>
  <brief_title>Comparison of Lower Limb Endovascular Interventions With and Without the EndoNaut Workstation</brief_title>
  <acronym>COMPAR-MI</acronym>
  <official_title>Comparison of Lower Limb Endovascular Interventions With and Without the EndoNaut Workstation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therenva</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CH Libourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Therenva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that the use of EndoNaut for endovascular procedures on the femoropopliteal&#xD;
      axis has a clinical impact for the patient (decrease in irradiation and the volume of&#xD;
      contrast product) as well as for nursing staff (reduction in irradiation) compared to&#xD;
      procedures performed without EndoNaut.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral artery disease (PAD) is characterized by a narrowing of the size of arteries,&#xD;
      which resulting in a loss of hemodynamic load. Endovascular (or percutaneous) procedures&#xD;
      performed at the infrainguinal level (axefemoro-popliteal) are very common in affected&#xD;
      patients. Therenva offers a complete and consistent lightweight navigation solution&#xD;
      (EndoNaut®) based on artificial intelligence (AI) algorithms, and providing technology&#xD;
      accessible to all operating rooms for PAD procedures. The aim of this study is to demonstrate&#xD;
      that the use of EndoNaut for endovascular procedures on the femoropopliteal axis has a&#xD;
      clinical impact for the patient (decrease in irradiation and the volume of contrast product)&#xD;
      as well as for nursing staff (reduction in irradiation) compared to the procedures performed&#xD;
      by EndoNaut.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">July 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of contrast product used during the routine care procedure (ml)</measure>
    <time_frame>1 day At enrollment</time_frame>
    <description>Volume are reported in mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Irradiation parameters: evaluation of the Fluoroscopy duration (min)</measure>
    <time_frame>1 day At enrollment</time_frame>
    <description>Parameter given by the X-ray imaging device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Irradiation parameters: dose-area quantification (mGy/m2)</measure>
    <time_frame>1 day At enrollment</time_frame>
    <description>Parameter given by the X-ray imaging device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Irradiation parameters: measurement of air Kerma (mGy)</measure>
    <time_frame>1 day At enrollment</time_frame>
    <description>Parameter given by the X-ray imaging device</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Procedures with EndoNaut</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Procedures without Endonaut</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovascular procedure</intervention_name>
    <description>Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.</description>
    <arm_group_label>Procedures with EndoNaut</arm_group_label>
    <arm_group_label>Procedures without Endonaut</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic occlusive arthritis of the Lower Limbs with lesions on the&#xD;
        femoro-popliteal stage and candidates for endovascular treatment of these lesions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with peripheral arterial disease of the lower limbs, all clinical stages,&#xD;
             lesions of the femoro-popliteal stage and candidates for endovascular treatment of&#xD;
             these lesions.&#xD;
&#xD;
          -  Major patients&#xD;
&#xD;
          -  Patients not opposed to their participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients requiring conventional surgical revascularization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CH Libourne</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

